Merck KGaA Builds New US Facility for Gene Therapy Products
April 21 2020 - 9:07AM
Dow Jones News
By Olivia Bugault
Merck KGaA said Tuesday that it has invested 100 million euros
($108.9 million) for the construction of a new facility in
California that will increase its gene therapy capacity.
The German pharmaceuticals and chemicals company said the
facility, which should open next year, will be used for its
BioReliance(R) viral and gene therapy service offering.
Merck KGaA already has a facility in California manufacturing
gene therapies.
"Merck's new, 140,000-square-foot manufacturing facility will
support viral and gene therapy production at the 1000-liter scale
using its Mobius(R) single-use equipment," it said.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
April 21, 2020 08:52 ET (12:52 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Apr 2023 to Apr 2024
